Announcements Trials
Browse Landscape

Phase

Phase NA 58Phase 2 33Phase 1 12Phase 3 5Phase 1/2 3Phase EARLY_PHASE1 2Phase 4 1

Status

Recruiting 2Suspended 1

Sponsor Class

INDUSTRY 4OTHER 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3Head & Neck 2Genitourinary 2Thoracic 1Sarcoma 1NET 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 178Leukemia 170Recurrence 163Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Interventions

tivozanib 1atezolizumab 1aldesleukin 1Adoptive Transfer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Vulvar Neoplasms × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07433283 2026-02-25

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Sichuan Enray Pharmaceutical Sciences Company

Phase 1/2 Recruiting
54 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡